Celgene has partnered with Bluebird bio to discover, develop and commercialise novel disease-altering gene therapies in oncology that utilise a patient’s own genetically modified T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells selectively. Celgene has the option to license collaboration products on completion of each Phase I study; bluebird will be responsible for R&D up until this point. In a separate deal, Celgene has also formed a collaboration with the Center for Cell and Gene Therapy in the CAR T-cell field.